THCV

THCV (tetrahydrocannabivarin) is one of the most therapeutically interesting minor cannabinoids in cannabis, and one of the most chemically distinct. THCV is a propyl analog of THC — meaning it has the same molecular structure but with a 3-carbon propyl side chain instead of THC's 5-carbon pentyl chain. This small structural difference creates dramatically different pharmacological behavior. Found primarily in African landraces (Durban Poison, Power Plant) and Southeast Asian sativas, THCV concentrations rarely exceed 1-2% in standard hybrids but can reach 5-15% in selectively bred high-THCV strains like Doug's Varin, Pineapple Purps, and Skunk #1 phenotypes. Mechanism of action: at low doses (under 10mg), THCV acts as a CB1 partial antagonist, BLOCKING THC binding at CB1 receptors and producing the opposite effects of THC — appetite suppression (vs THC's munchies), increased energy and focus (vs THC's sedation potential), reduced anxiety (vs THC's anxiety-induction risk), and clear-headed cerebral activation. At higher doses (above 20mg), THCV switches to CB1 agonism similar to THC, producing mild euphoria. Documented and emerging therapeutic potential: type 2 diabetes (THCV improves insulin sensitivity and glucose tolerance in clinical trials), obesity treatment (appetite suppression without the side effects of pharmaceutical anti-obesity drugs), Parkinson's disease (neuroprotective effects in animal models), bone growth stimulation (CB2-mediated bone formation), reduced PTSD symptoms (clinical trial data emerging), and reduced anxiety. The pharmaceutical industry has begun developing THCV-based medications: GW Pharmaceuticals (now Jazz Pharmaceuticals) has THCV in clinical trials for type 2 diabetes. Recreational interest is also growing — THCV strains marketed as "diet weed" have appeared in California and Nevada dispensaries. THCV is decarboxylated like THC at slightly higher temperatures (around 428°F vs 220°F).